Healthcare sales up 15% at Novo Nordisk:
This article was originally published in Clinica
Healthcare sales at Novo Nordisk (Denmark) rose 15% to DKr 2,365 million ($438 million) in the first quarter of 1995 compared with the previous year. This reflects developments in the volume/product mix, says the company. Diabetes care revenues were up DKr 1,610 in the quarter compared with 1994. Stronger sales in Germany, Japan and the UK were counteracted by a decline in US sales, which Novo blames on negative currency exchange movements. Group turnover was up 9% to DKr 3,404 million for the quarter, with net income up 15% to DKr 310 million, compared with the same period last year. The group expects overall revenues to increase some 10% in 1995.
You may also be interested in...
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.